[In these days molecule target drug in advanced non-small cell lung cancer].
Conventionally advanced-non-small cell lung cancer have been treatment platinum and 90S new drug (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan). However survival benefit is several months and treatment outcome have arrives at plateau. One molecule target drug have been attract attention. In this chapter mainly on gefitinib that refer that have been to data that clinical trial and EGFR gene mutation and resistance to EGFR-TKI. EGFR mutation with an initial dramatic response acquired resistance to the EGFR-TKI. Until the present that stracture have been participate T790M for acquired resistance and amplification of the MET gene is another mechanism of acquired resistance to EGFR-TKI.
Miyazaki
M
M
Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Japan.
Nakagawa
K
K
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D011799:Quinazolines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib